GOSS News and Press, Gossamer Bio Inc. From 05/06/21

– Seralutinib and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively – – Cash, cash equivalents and marketable securities totaled $453 m...

Gossamer Bio (GOSS) announces that Luisa Salter-Cid, the company's Chief Scientific Officer, will resign effective April 30, 2021.The company's Senior Vice President, Research & Translational Biology, Laura Carter, will be promoted to the role upon Salter-Cid's departure.Ca...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Luisa Salter-Cid, Ph.D., Gossamer’s...

Clinical-stage biopharmaceutical company Gossamer Bio (GOSS) announces the promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs.Peterson previously served as Senior Vice President, Regulatory & Quality after joining Gossamer in 2018.He will ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the promotion of Caryn Peterson to Executive Vi...

Gossamer Bio, Inc. (GOSS) Q4 2020 Earnings Conference Call February 25, 2021 08:30 A.M. ET Company Participants Bryan Giraudo - CFO Faheem Hasnain - Co-Founder, CEO, & Chairman Richard Aranda - SVP, Clinical Development Conference Call Participants Unidentified Analyst - Carter Gould - Ba...

Gossamer Bio (GOSS): Q4 GAAP EPS of -$0.88 misses by $0.09.Cash, equivalents and marketable securities totaled $512.6M.Seralutinib (GB002) and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension and Ulcerative Colitis, res...

- Seralutinib (GB002) and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively - - Topline results for both ongoing Phase 2 trials expected in the first half o...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its fourth quarter and full-yea...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...